Vizsgálati helyszín
Icon Cancer Centre Kurralta Park
Kurralta Park, 5037, AusztráliaMég nincs intézményhez kötve
- 17futó vizsgálat
- 1lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 18 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis9 vizsgálat
- 2. fázis4 vizsgálat
- 1. fázis2 vizsgálat
- 2/3. fázis2 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Toboroz12 vizsgálat
- Fut, nem toboroz5 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- Pfizer5 vizsgálat
- Janssen Research & Development, LLC3 vizsgálat
- BioNTech SE2 vizsgálat
- Eli Lilly and Company2 vizsgálat
- Frontier Medicines Corporation1 vizsgálat
- és még 5
Futó vizsgálatok
Toboroz
A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
NCT07832292· 2. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266· 3. fázis· Ono Pharmaceutical Co., Ltd.· Forrás
Contact: Cathy Murphy
Toboroz
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· 3. fázis· Incyte Corporation· Forrás
Toboroz
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437· 2/3. fázis· Pfizer· Forrás
Toboroz
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· 3. fázis· Pfizer· Forrás
Toboroz
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· 3. fázis· Eli Lilly and Company· Forrás
Contact: Dainik Patel (principal investigator)
Fut, nem toboroz
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06909825· 2. fázis· Fusion Pharmaceuticals Inc.· Forrás
Toboroz
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355· 3. fázis· BioNTech SE· Forrás
Toboroz
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· 2/3. fázis· BioNTech SE· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478· 2. fázis· Loxo Oncology, Inc.· Forrás
Contact: Ka Chun Cheung (principal investigator)
Toboroz
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470· 1. fázis· MacroGenics· Forrás
Contact: Global Trial Manager
Fut, nem toboroz
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT06244771· 1/2. fázis· Frontier Medicines Corporation· Forrás
Contact: Sue Yeend
Fut, nem toboroz
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844· 3. fázis· Janssen Research & Development, LLC· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek